Considering that the PI3K/Akt and MEK/ERK1/2 pathways are two major downstream signaling pathways of activated EGFR in glioma [50], therapeutic approaches for the inhibition of these signaling pathways are being actively studied [24]. Here, AKT1 is linked to central nervous system cancer.